Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for RLAY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
June 30, 2026 890.01M
March 31, 2026 642.18M
December 31, 2025 567.06M
September 30, 2025 607.71M
June 30, 2025 665.66M
March 31, 2025 721.08M
December 31, 2024 777.79M
September 30, 2024 838.86M
June 30, 2024 681.74M
March 31, 2024 745.76M
December 31, 2023 752.00M
September 30, 2023 778.37M
June 30, 2023 810.12M
March 31, 2023 883.41M
Date Value
December 31, 2022 950.22M
September 30, 2022 999.77M
June 30, 2022 779.64M
March 31, 2022 841.97M
December 31, 2021 897.81M
September 30, 2021 571.09M
June 30, 2021 618.53M
March 31, 2021 732.79M
December 31, 2020 763.29M
September 30, 2020 713.52M
June 30, 2020 312.39M
March 31, 2020 335.43M
December 31, 2019 357.34M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Insmed, Inc. 757.49M
United Therapeutics Corp. 6.400B
AbbVie, Inc. -5.935B
TG Therapeutics, Inc. 604.08M
Travere Therapeutics, Inc. 24.52M

Shareholders Equity (Quarterly) Related Metrics